Center of Excellence on Compounding for Outsourcing Facilities -Operating Costs

The Food and Drug Administration is forecasting a future procurement opportunity for the Center of Excellence on Compounding for Outsourcing Facilities, specifically focused on covering operating costs. This initiative is intended to support advanced compounding capabilities within outsourcing facilities, likely aiming to enhance the safety, quality, and reliability of compounded pharmaceutical products. The effort falls under the NAICS code 541990, indicating it pertains to other scientific and technical consulting services, suggesting the award will involve specialized operational, technical, or administrative support rather than direct manufacturing. The contract will be managed by the FDA’s Center for Drug Evaluation and Research, with the program point of contact available via cderacquisitions@fda.hhs.gov, while the contracting officer position has yet to be assigned. No set-aside designation has been indicated, meaning the opportunity will be open to all eligible contractors without preference for small businesses or other categories. The place of performance and physical location have not been specified, allowing flexibility for the selected entity to operate remotely or on-site as required. The forecast was posted on May 25, 2026, and is intended to provide industry stakeholders advance notice to prepare proposals or coordinate capabilities. No solicitation number has been issued yet, and the formal request for proposals has not been released, but interested parties should monitor the HHS OSDBU portal for upcoming updates and formal announcements.